医学
肥厚性心肌病
药物遗传学
心肌病
心脏病
叙述性评论
生物信息学
疾病
药代动力学
重症监护医学
肌球蛋白
心脏病学
内科学
冠状动脉疾病
心房颤动
心室流出道梗阻
治疗方法
药理学
扩张型心肌病
临床试验
梅德林
作者
Lianglei Hou,Bin Lin,Xiaojun Ji,Anwu Huang
摘要
Hypertrophic cardiomyopathy (HCM) is a common inherited disease with substantial residual morbidity despite established pharmacological and surgical therapies. We conducted a narrative review of the current evidence on cardiac myosin inhibitors, drawing on published studies up to July 2025, including pivotal clinical trials, real-world cohorts, and pharmacokinetic analyses. Mavacamten and Aficamten consistently reduced left ventricular outflow tract (LVOT) gradients, improved New York Heart Association class, and were generally well tolerated under echocardiography-guided titration. Long-term extensions and real-world registries confirmed sustained efficacy, while pharmacogenetic factors and monitoring strategies continue to shape individualized use. Comparative analyses suggest Aficamten offers more rapid pharmacokinetics and simplified dosing, though both require careful safety surveillance. Remaining challenges include limited data in non-obstructive HCM, uncertain antifibrotic and rhythm outcomes, high cost, and the burden of frequent imaging and genetic testing. Beyond HCM, early studies are exploring broader indications and next-generation modulators. Cardiac myosin inhibition is reshaping the therapeutic landscape of HCM, but cost-effective, precision-based implementation and long-term outcome studies remain critical priorities.
科研通智能强力驱动
Strongly Powered by AbleSci AI